Healio

Genentech voluntarily recalls Susvimo ocular implant

Please provide your email address to receive an email when new articles are posted on . Genentech is voluntarily recalling the Susvimo implant and insertion tool for the treatment of wet age-related ...
pharmaphorum

FDA expands label for Roche's eye disease implant Susvimo

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema (DME), a leading cause of vision loss and blindness.
Yahoo Finance

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeks Susvimo offers the first alternative to regular eye injections that ...
Nasdaq

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...
Pharm Exec

FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye ...
Business Wire

New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss

‒ In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one – ‒ ...
The Globe and Mail

Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the ...
Pharmabiz

US FDA approves Roche’s Susvimo for intravitreal use via ocular implant to treat neovascular or “wet” age-related macular degeneration

Roche announced that the US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with ...
Business Wire

FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)

‒ Susvimo, previously called Port Delivery System with ranibizumab, is the first wet AMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a ...
Nasdaq

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III ...
The Globe and Mail

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the ...